Extension Study of Long-term Safety and Efficacy of Tulisokibart
Phase 3
1,380
about 13 years
All ages
12 sites in CT, MI, MO +4
What this study is about
Researchers are testing the safety and effectiveness of tulisokibart over a long period in people with Crohn's disease or ulcerative colitis. The trial is for people who previously received tulisokibart in other studies.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Placebo to tulisokibart
- 2.Take Tulisokibart
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Number of Participants Who Discontinue Study Treatment Due to an AE, Number of Participants Who Experience an Adverse Event (AE)
Secondary: Percentage of Participants with Crohn's Disease Achieving Clinical Remission per Stool Frequency and Abdominal Pain Score
Gastroenterology